Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Depomed Inc Reaffirms FY 2013 Revenue Guidance-Conference Call


Monday, 29 Jul 2013 09:00am EDT 

Depomed Inc reaffirmed fiscal 2013 revenue guidance and expects total revenues of approximately $125 to $135 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $125 million for fiscal 2013. 

Company Quote

11.04
-0.7 -5.96%
28 Jul 2014